Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Share issue with gross proceeds almost EUR 6 million

Keliber Oy (“Keliber” or “the Company”) has successfully raised EUR 5.77 million through directed share issue to the current shareholders and personnel of the Company.Based on the authorization received from the Annual General Meeting of the Shareholders, the Board of Directors of Keliber has approved the subscriptions made in the share issue directed to the current shareholders of the Company and the personnel of the Company. In the issue total of 175 119 new shares were subscribed. The gross proceeds of the share issue were EUR 5.77 million. Subsequent of the directed share issue the

BioStock: Fluicell at the forefront of 3D bioprinting

Drug discovery and development is extremely time-consuming. To facilitate the drug discovery process, biotech companies have set out to develop new tools aimed at helping researchers get better results at lower costs. One example is Fluicell, a Swedish company with a strong product portfolio with the promise of answering that call. We caught up with the company’s CEO, Dr Victoire Viannay, to learn more about their technology.Read the full interview with Fluicell's CEO Victoire Viannay at biostock.se: https://www.biostock.se/en/fluicell-at-the-forefront-of-3d-bioprinting/ This is a

aXichem signs distribution agreement with STEFES Ingredients for sales and distribution of aXivite® in Germany

aXichem AB (publ), that develops and markets natural analogue industrial compounds, has signed a marketing, sales and distribution agreement with the German company STEFES Ingredients, a provider of raw materials for food supplements, functional foods and beverages, regarding aXichem’s capsaicin analogue product, aXivite for dietary supplement.    – I am very pleased with having entered into this agreement with STEFES Ingredients. STEFES has a history of proven success as a distributor of raw materials in the area that we target with aXivite. I’m looking forward to our collaboration

FundedByMe CEO Daniel Daboczy invests in ongoing rights issue*

FundedByMe CEO Daniel Daboczy subscribes to 55,554 shares for a total of SEK 122,218 in the ongoing rights issue. The rights issue is 100 percent guaranteed and the subscription period runs until March 27.“All of FundedByMe’s, Laika’s and Feminvest's tools are built to help companies. The current turbulence and turmoil of the markets are affecting all of us right now, but we look forward to being able to help even more companies in the future. During these times, I have personally chosen to invest in FundedByMe as I see the potential of the company and its future, where the capital market

Enzymatica signs agreement with Chemipal for Israel

Enzymatica has entered into a distributor agreement with the leading pharmaceutical distributor Chemipal for marketing and sales of ColdZyme® in Israel. The OTC market in Israel has annual sales of million 200 USD and the cold market is estimated to million 20 USD[1].Chemipal will sell ColdZyme to the two main pharmacy chains, Super-Pharm and BE, and to private pharmacies and sick funds. The company will carry out an extensive marketing campaign involving advertising, radio commercials, digital communication, social media and PR. In addition, Chemipal will offer information and training of

Open day C-RAD and Singleton Hospital, Swansea Bay

C-RAD is pleased to announce that Singleton Hospital in Swansea Bay/ Wales welcomed users and interested customers for an open day to demonstrate workflow integration and usability of the SIGRT solution.After a welcome from Dr Ryan Lewis, Head of the Radiotherapy Physics the meeting started with at around 35 attendees. “SIGRT is an exciting and fast emerging technology, which we think will have a massive positive impact on the quality of radiotherapy treatment that we can offer for our patients at the South West Wales Cancer centre. With staff from many nearby Radiotherapy centres also

Acquisitions of own shares in Evolution Gaming Group AB (publ)

Evolution Gaming Group AB (publ) (“Evolution”) has, during the period 16 March 2020 – 17 March 2020, acquired a total of 338,000 own shares within the framework of the repurchase programme introduced by the board of directors to improve the capital structure of Evolution by reducing the capital, and thereby creating added shareholder value.The repurchase programme, which Evolution announced on 16 March 2020, is being implemented in accordance with the EU Market Abuse Regulation No 596/2014 (“MAR”) and Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”).During the

AVTECH informs that the contract process for an Aventus Full-flight winds service agreement, valued at approximately SEK 1 to 2 million, has been paused

AVTECH Sweden AB informs that the signature process for an Aventus NowCast Full-flight Wind Uplink service agreement with a European charter airline group has been paused until further notice due to the present COVID-19 situation. Under this agreement AVTECH will be providing highly accurate and tailored weather uplinks to the UK, Belgian, Dutch and Swedish subsidiaries, operating a total of 120 aircraft of both short- and long-haul type. The two-year service agreement will have an expected value between 1 and 2 MSEK, dependent on fleet utilisation, and includes an evaluation of benefits

Coor extends IFM agreement with Vasakronan

Coor has extended its agreement with Vasakronan regarding IFM delivery of property- related services in Stockholm, Gothenburg, Uppsala and Malmö.Coor’s contract with Vasakronan generates annual sales of some SEK 200 M. The agreement which is now being extended is worth some SEK 120 M annually and runs until 2023. In addition, Coor also delivers conference and restaurant services in Vasakronan’s premises worth some SEK 85 M annually.   Over the coming years, Coor and Vasakronan will continue to jointly develop new services and concepts focusing on sustainability and making everyday

Information in relation to COVID-19

Due to the global spread of COVID-19, Evolution Gaming provides the following comment to the development. Daily operations have been conducted without any large disturbances up until this point, and the demand for the company’s products continue to be strong.Evolution works with precautionary measures in all studios, including disinfection, distancing and separation of employees, temperature checks at studio entrances, increased cleaning, hand hygiene and several other infection prevention activities. In total, Evolution operates studios in 8 locations, and the company’s routines for

Practical guidelines for SRV Group Plc's Annual General Meeting due to coronavirus

SRV GROUP PLC    STOCK EXCHANGE RELEASE         20 MARCH 2020     09:30 EET   Practical guidelines for SRV Group Plc's Annual General Meeting due to coronavirus   Due to the risk of the coronavirus spreading, SRV Group Plc publishes practical guidelines for the Annual General Meeting to be held on Thursday, 26 March 2020 at 4:00 pm to ensure the safety of shareholders and SRV personnel. We will follow all regulatory guidelines in arranging the event. We will update our guidelines at www.srv.fi/agm as necessary. Shareholders are asked to follow this website for up-to-date

Notice of Annual General Meeting of Troax Group AB (publ)

PRESS RELEASE, Hillerstorp, 20th of March 2020, at 08.30 CETThe shareholders of Troax Group AB (publ) (556916-4030) are hereby invited to the Annual General Meeting on Tuesday, April 23rd, 2020 at 3 pm at the company's office, Tyngel, 335 04 Hillerstorp. As a precautionary measure to reduce the risk of spreading the covid-19 corona virus, Troax Group AB intends to keep the AGM very short and effective. No refreshment or mingling will be offered. Scheduled speeches will be limited to a few minutes or will be cancelled in order to limit the length of the meeting, which is estimated to be

Notice of Annual General Meeting in Rejlers AB (publ)

The shareholders of Rejlers AB (publ) (the “Company”), reg. no 556349-8426, are hereby summoned to the Annual General Meeting on Wednesday, 22 April 2020 at 4:00 p.m. at Lindhagen Conference Centre, Lindhagensgatan 126 in Stockholm, Sweden. Registration for the meeting commences at 2:30 p.m.Notification Shareholders who wish to participate in the Annual General Meeting must: i. both be recorded as shareholders in the share register kept by Euroclear Sweden AB on the record date of Thursday 16 April 2020; andii. have notified their participation to the Company not later than

Notice of the Annual General Meeting (AGM) of PostNord AB (publ)

Notice is hereby provided of the Annual General Meeting (AGM) of PostNord AB (publ), (corp. id. no. 556771-2640).Time: 2.00 p.m., Wednesday, 22 April 2020 Venue: PostNord’s head office, Terminalvägen 24, Solna, Sweden   Right to participate and registration   Shareholders Shareholders wishing to take part in the Annual General Meeting must be entered in the share register maintained by Euroclear Sweden AB by Thursday 16 April 2020.   Shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own name to be

Read original

Immunovia publishes the annual report for the financial year 2019

LUND, SWEDEN - Immunovia has today published the annual report for 2019. It is available on Immunovia's website .   Mats Grahn, CEO, comments: "In December 2019, we reached a very important milestone with the results of the “Commercial Test Model Study”, which showed 95% accuracy for IMMray™ PanCan–d, our product for diagnosing pancreatic cancer at an early stage when it is still possible to successfully remove the tumor surgically. This result paves the way for considerable improved treatment and survival rates for patients with

Arcus ASA: Annual General Meeting 2020 is postponed

Arcus postpones its Annual General Meeting convened for 21 April 2020 to a later date.Based on the 2019 results, the Board of Directors had proposed a dividend in line with last year’s. In light of current uncertainty in society, due to the coronavirus outbreak, the Board of Directors believes the responsible action is to await further developments before making a dividend proposal and arranging the Annual General Meeting. Therefore, today the Board of Directors has decided to cancel the Annual General Meeting convened for 21 April 2020. The Board of Directors will convene the Annual

Finnair strengthens its funding position. The Ministerial Committee on Economic Policy has proposed that the State of Finland guarantees the pension premium loan included in the plan

Finnair Plc                  Stock Exchange Release                 20 March 2020 at 9.05 a.m. EET  Finnair announced in its Stock Exchange Release on 16 March 2020 that it is implementing a substantial funding plan in order to secure the company’s future even in a prolonged coronavirus situation. The plan includes funding instruments such as available credit lines, sale and leasebacks of unencumbered aircraft and a substantial, market-based pension premium loan. The available credit lines included in the funding plan consist of a revolving credit facility totaling to 175 million

Director/PDMR Shareholding

20 March 2020 07:00 GMT   Transaction by Person Discharging Managerial Responsibilities Disclosure under Article 19 of the EU Market Abuse Regulation   AstraZeneca PLC (the Company) announced that, on 19 March 2020, it was notified by Tony Mok, a Non-Executive Director of the Company, that, on 18 March 2020, Mr Mok purchased 1,000 of the Company's American Depositary Shares (ADSs) at a price of $38.32 per ADS. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.   The attached notification, made in accordance with the requirements of the EU Market

Annual General Meeting in AQ Group AB (publ) on April 22, 2020

The Annual General Meeting in AQ Group AB (publ) will be held on Wednesday, April 22, 2020 at 18:00 at Aros Congress Center, Hörsalen plan 1, Västerås, Sweden.   Notice of the Annual General Meeting, with proposed agenda is included in its entirety in this press release and is published on the company web page www.aqg.se . The notice of the meeting is published in "Post- och Inrikes Tidningar" and an announcement with information that the notice has been issued is published in Dagens

Ole Kristian Jødahl appointed President and CEO of Alimak Group, effective as of June 1, 2020

The Board of Directors of Alimak Group has appointed Ole Kristian Jødahl as President and CEO of Alimak Group, effective as of June 1, 2020. Ole Kristian Jødahl is to succeed Tormod Gunleiksrud, who will, as previously communicated, leave the company after 8 years as President and CEO.   Ole Kristian Jødahl will join Alimak Group from the assignment as CEO of Hultafors Group. He has previously worked with operations management and held operational positions within SKF Group, most recently as Director, Sales & Marketing, Industrial Market, SKF Group. Ole Kristian Jødahl is a Norwegian

Procedures at Fabege’s Annual General Meeting on 2 April 2020

Due to the risk of contagion from Convid-19, Fabege will have special procedures in place at the Annual General Meeting on 2 April 2020.These procedures include the following: · Shareholders (private individuals, not legal entities) are being offered representation at the Annual General Meeting by proxy through, an employee of Euroclear Sweden AB. · In light of the authorities’ regulations, we would urge all shareholders to carefully consider using this opportunity to provide a power of attorney and voting instructions to a specially designated representative of Euroclear instead of

Atrium Ljungberg borrows SEK 920 million from Nordic Investment Bank

Atrium Ljungberg has signed a green bank loan from Nordic Investment Bank for SEK 920 million. The loan is unsecured and the time to maturity is seven years. The funds will be used in the development of the Life City project in Hagastaden, Stockholm.Atrium Ljungberg is a long-term property owner with a strong financial position. Its loan portfolio amounts to approximately SEK 20 billion, half of which is financed through the capital markets. The remainder consists of bank financing and direct lending. The unsecured bank loan of SEK 920 million is Atrium Ljungberg's first with Nordic

CONTINUED GROWTH AND INCREASED FOCUS ON PROFITABILITY

This is a translation of the Swedish interim report. If there should be any discrepancies, the Swedish language version governs.   FOURTH QUARTER, OCTOBER – DECEMBER 2019 · Net sales increased by 12.0%, or 10.7% FX adjusted, to MSEK 70.5 (63.0) · Gross profit increased by 7.7%, or 6.1% FX adjusted, to MSEK 54.0 (50.2) · EBIT was MSEK -5.3 (-3.6) · Earnings after tax was MSEK -6.2 (-2.9) · Earnings per share was, basic SEK -0.79 (-0.40), diluted SEK -0.79 (-0.40)   FULL YEAR, JANUARY – DECEMBER 2019 · Net sales increased by 8.9%, or 7.5% FX adjusted, to MSEK

Final Results for the year ended December 31, 2019

Faron Pharmaceuticals Oy ("Faron" or the "Company")   Financial statement release January 1 to December 31, 2019   Financial statement release, Turku, 20 March 2019 at 9.00 AM (EET) Inside information   TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today reports its financial statements for the year ended 31 December 2019 and H2 2019.   HIGHLIGHTS   Operational (including post period):   Clevegen[®] - Regulator of major inhibitory immune checkpoints and wholly-owned novel

There are no items matching the current filter
There are no more items matching the current filter
Back to top